The 1st world center to defeat the most serious infection: sepsis

Camille Galap, president of the University of Paris-Saclay, Nicolas Revel, director general of Assistance Publique – Hôpitaux de Paris (AP-HP), Anne-Isabelle Étienvre, director of fundamental research at the CEA and Didier Samuel, president director General of the National Institute of Health and Medical Research (Inserm) opened the morning of the launch of theIHU Prometheusin the presence of Sylvie Retailleau, Minister of Higher Education and Research. IHU Prometheus is the first global institute dedicated to the fight against sepsis, integrating researchers, caregivers, patients, institutions and private partners, within an ecosystem of prevention, care, research, training and technology transfer.

The creation of the IHU aims to promote the development of new diagnostic tests and new drugs to reduce by half in ten years the health, social and economic burden represented by sepsis.

This was confirmed by Mervyn Singer, president of the independent, international Scientific Council of the IHU, Jamila Hedjal, president of the France Sepsis Association and Marisol Touraine, president of the IHU Supervisory Board who also spoke in introduction to the morning.

A triple scientific ambition for precision medicine:

. a better understanding of the molecular and cellular interactions between the host and the pathogens at the origin of the progression of uncomplicated infection towards sepsis, the establishment of a longitudinal cohort of 10,000 patients followed over 10 years, unique in the world allowing a better understanding of long-term sepsis and its social and economic consequences;

. the validation and commercialization of a rapid testing platform to finely characterize at the level of each individual the host response to infection and therapeutic targets and the creation of a specific digital twin of sepsis to precisely anticipate the response of each individual to different treatments;

. the development of new treatments such as innovative small molecules, nanomedicines, biotherapies, vaccines and strategies modulating microbiota.